EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer

Kota Itahashi, Akihito Kawazoe, Tadayoshi Hashimoto, Yue Yan, Takuma Irie, Hiromi Ono, Hitomi Tamura, Kyoko Hongo, Takashi Ikeno, Masashi Wakabayashi, Akihiro Sato, Yoshiaki Nakamura, Takao Fujisawa, Tomohiro Iwasawa, Tomoya Suzuki, Izuma Nakayama, Yasuhiro Kojima, Takayuki Yoshino, Hiroyoshi Nishikawa, Shohei Koyama, Kohei Shitara

Science Translational Medicine · 2026-11-04 · 18 (874)

DOI: 10.1126/scitranslmed.aec7235 ↗
AbstractBibliografische Angaben

Abstract

Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair–proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells. At progression, LRRC15 + CAFs and APLN + tip cells remained reduced, activated CCR8 + regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1 + lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →